Interest of Plasma microRNAs

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

58 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-05-31

Study Completion Date

2017-05-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

ICU acquired muscle weakness (IAMW) is a common disease that is associated with high morbidity and mortality. Patients with septic shock are particularly at risk.

The diagnosis of IAMW is clinical and based on the rating of the Medical Research Council score (MRC score). A MRC score lower than 48 defines the IAMW. But this evaluation is only usable in sufficiently awaken patients.

Several studies have highlighted the role of microRNAs in regulating physiological processes and diseases related to the skeletal muscles. To date, no study was interested in IAMW.

The aim of this study is to compare the microRNA detection kinetics on the appearance of IAMW.

In septic shock patients, the kinetics of nine microRNAs will be compared between two groups: those with IAMW (IAMW + group) and those without IAMW (IAMW - group).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Muscle Function and Muscle Ultrasound in ICU

NCT04696497

Muscle Weakness

TERMINATED NA

Muscle Force Assessment in the Intensive Care Unit and in Primary Myopathies

NCT00735384

Sepsis Primary Myopathies

COMPLETED

Prognostic Factors , Morbidity and Mortality in Patients With Neuromuscular Disorders Admitted in ICU

NCT02685215

Muscular Dystrophies Intensive Care (ICU) Myopathy

UNKNOWN

Characterization and Longitudinal Monitoring of Muscular Phenotype in Patients Admitted to Intensive Care for Sepsis

NCT07074028

Sepsis Myopathy Critical Illness

RECRUITING NA

Use of Neurostimulation As a Tool for Reconditioning the Neuromuscular System of Patients Admitted to the ICU for Septic Shock

NCT05257759

Septic Shock

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

MicroRNAs (miR-1, miR-21, miR-133, miR-155, miR-206, miR-208a, miR-208b, miR-486, miR-499) will be measured at day 1, day 2, day 5 and day 7 after septic shock onset.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Septic Shock

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ICU acquired muscle weakness (IAMW) group +

The Medical Research Council score (MRC score) is lower than 48, defining an ICU acquired muscle weakness (IAMW).

Kinetic of microRNAs is measured

kinetic of microRNAs

Intervention Type OTHER

blood samples will be drawn to measure microRNAs

ICU acquired muscle weakness (IAMW) group -

The Medical Research Council score (MRC score) is higher than 48. Kinetic of microRNAs is measured

kinetic of microRNAs

Intervention Type OTHER

blood samples will be drawn to measure microRNAs

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

kinetic of microRNAs

blood samples will be drawn to measure microRNAs

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients with septic shock criteria:

* At least two of the following criteria: temperature \< 36 ° C or \> 38 ° C, heart rate \> 90 beats / minute, respiratory rate\> 20 breaths / minute or PaCO2 \< 32mmHg, leukocytes \> 12,000 / mm3 or \< 4000 / mm3
* Refractory Hypotension (blood pressure \< 90mmHg or need norepinephrine) or lactate ≥ 4 mmol / L

Exclusion Criteria

* Age\<18years
* Patients with preexisting neuromuscular disease
* Pregnancy
* Moribund patients with early therapeutic limitation
* Patients who had a seizure in the last 6 months

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No